[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thrombotic-thrombocytopenic-purpura\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thrombotic-thrombocytopenic-purpura":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,55,88],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":40,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100572008","longitudinal-cohort-of-thrombosis-and-hemostasis-diseases-100572008",false,"NCT06727669","Longitudinal Cohort of Thrombosis and Hemostasis Diseases","Inclusion Criteria:\n\n* Patients who were diagnosed as thrombosis and hemostasis diseases.\n\nExclusion Criteria:\n\n* Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease.\n* Patients with alcohol and drug addictions or mental illness affect their ability to comply with study requirements.\n* According to the investigator, there are conditions that may endanger the patient's safety or affect his\u002Fher compliance.",true,"ALL",{"count":18,"type":19},3000,"ESTIMATED","5 Years","OBSERVATIONAL","This is a multicenter, prospective, longitudinal, observational cohort study to investigate thrombosis and hemostasis diseases in Chinese patients. This study will collect basic information, diagnostic and treatment information, as well as medical expense information of patients from medical records.The incidence and risk factors of thrombosis and hemostasis diseases, the treatment methods, prognosis and medical expenses of these patients in China will be analyzed. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.",[24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39],"Immune Thrombocytopenia","Thrombotic Thrombocytopenic Purpura","Hemophilia A, Acquired","Disseminated Intravascular Coagulation","Thrombophilia","Deep Vein Thrombosis","Pulmonary Embolism","Thrombotic Microangiopathies","Coagulation Factor Deficiency","Hemophilia A","Hemophilia B","Hemophilia B, Acquired","Platelet Dysfunction","Arterial Thromboembolism","Bleeding Disorder","Thrombosis",[39,41],"Hemostasis","RECRUITING","2024-12-05",{"date":45,"type":46},"2024-12-11","ACTUAL",{"date":48,"type":46},"2024-11-01",{"date":50,"type":19},"2030-12-31",{"name":52,"class":53},"Peking University People's Hospital","OTHER",5,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":65,"conditions":66,"keywords":71,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100152520","genotype-and-phenotype-correlation-in-hereditary-thrombotic-thrombocytopenic-purpura-upshaw-schulman-syndrome-100152520","NCT01257269","Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)","Thrombotic Thrombocytopenic Purpura Registry - A Prospective Observational Study for Patients Suffering From Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)","TTP registry","Inclusion Criteria:\n\n* Severe ADAMTS13 deficiency ( ≤ 10% activity) and no ADAMTS 13 inhibitor on two or more occasions at least one month apart\n* Being a family member of a confirmed or suspected patient\n* Molecular analysis of ADAMTS13 gene with one or more mutations and\u002For positive infusion trial (full recovered ADAMTS13 activity after infused fresh frozen plasma (FFP) with a plasma half-life of 2-4 days)",{"count":64,"type":19},450,"Hereditary thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) is a rare disorder characterized by thrombocytopenia as a result of platelet consumption, microangiopathic hemolytic anemia, occlusion of the microvasculature with von Willebrand factor-platelet-thrombic and ischemic end organ damage. The underlying patho-mechanism is a severe congenital ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, 13) deficiency which is the result of compound heterozygous or homozygous ADAMTS13 gene mutations.\n\nAlthough considered a monogenic disorder the clinical presentation in Upshaw-Schulman syndrome patients varies considerably without an apparent genotype-phenotype correlation. In 2006 we have initiated a registry for patients with Upshaw-Schulman syndrome and their family members to identify possible triggers of acute bouts of TTP, to document individual clinical courses and treatment requirements as well as possible side effects of long standing plasma substitution, e.g. alloantibody formation or viral infections.",[25,67,68,69,70],"Congenital Thrombotic Thrombocytopenic Purpura","Familial Thrombotic Thrombocytopenic Purpura","Thrombotic Thrombocytopenic Purpura, Congenital","Upshaw-Schulman Syndrome",[72,73,74,75,76,77],"Thrombotic thrombocytopenic purpura","ADAMTS13","Von Willebrand factor","Von Willebrand factor cleaving protease","Thrombocytopenia","Hemolytic anemia","2023-10-10",{"date":80,"type":46},"2023-10-11",{"date":82,"type":4},"2006-10",{"date":84,"type":19},"2030-10",{"name":86,"class":53},"Insel Gruppe AG, University Hospital Bern",7,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":97,"phases":98,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":4},"100482908","phase-2-aspirin-for-prophylaxis-of-ttp-100482908","NCT05568147","Aspirin for Prophylaxis of TTP","A Prospective Multicenter Clinical Study of Aspirin for Prophylaxis in Patients With Hereditary or Acquired Thrombotic Thrombocytopenic Purpura","Inclusion Criteria:\n\n1. Those who voluntarily signed the informed consent form and were able to comply with the study protocol.\n2. Subjects diagnosed with severe ADAMTS13 deficiency, defined as ADAMTS13 activity \\\u003C10%, documented in the patient's medical history or at screening. Note: In patients receiving fresh frozen plasma (FFP) or other prophylactic treatments containing ADAMTS13 products, plasma ADAMTS13 activity levels at screening may exceed 10%. hTTP will be documented by ADAMTS13 activity \\\u003C10% and biallelic pathogenic ADAMTS13 mutations. Patients with hTTP may be asymptomatic. iTTP will be diagnosed by ADAMTS13 activity \\\u003C10% and the presence of an ADAMTS13 activity inhibitor (or comparable test for anti-ADAMTS13 antibodies). The diagnosis of hTTP may be supported by the recovery of ADAMTS13 activity to \\>10% during clinical remission.\n3. Subjects do not exhibit any severe symptoms of TTP at the time of screening. At screening, patients with mild but stable laboratory abnormalities (LDH not higher than three times the upper limit of normal; platelet count not less than 100,000\u002Fmicroliter) are eligible for enrollment.\n4. No stroke was detected on cranial MRI and there was no previous history of stroke.\n5. The subject is willing and able to comply with the requirements of this protocol.\n\nExclusion Criteria:\n\n1. Subject has a history of significant neurological events, such as a major stroke, indicating that a relapse may have serious consequences, as judged by the investigator\n2. Subject has increased risk for bleeding (e.g., platelet count \\\u003C30,000\u002FµL, severe coagulopathy, gastrointestinal disease)\n3. Subject has a history of drug and\u002For alcohol abuse within six months before enrollment.\n4. Subject has a life expectancy of fewer than three months.\n5. The investigator considers the subject unable or unwilling to cooperate with the study procedures.\n6. The subject is a family member or employee of the investigator.\n7. The patient is pregnant or breast-feeding.",{"count":96,"type":19},100,"INTERVENTIONAL",[99,100],"PHASE2","PHASE3","Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy characterized by thrombocytopenia, microangiopathic hemolytic anemia, and microvascular thrombosis causing neurological and renal abnormalities; it is associated with massive depletion of platelets in the microvasculature to form microthrombi1 . Long-term follow-up of patients with congenital TTP (cTTP) revealed frequent strokes and renal injury. Of 217 surviving patients, 62 (29%) had a stroke; the median age was 21 years. iTTP patients also require long-term follow-up. iTTP patients with low ADAMTS13 activity (\\\u003C70%) in remission have a 28% risk of stroke. Survival rates of iTTP patients in remission were lower than those of age-, race-, and sex-matched populations. In terms of stable treatment, maintenance therapy is not recommended for patients with iTTP. Previous studies have shown that aspirin may be able to prevent stroke complications in patients with cTTP and iTTP. In addition to its potential efficacy, the risks of aspirin are small and inexpensive. Aspirin is very effective in secondary prevention of stroke 6. However, the therapeutic value of aspirin in TTP has not been studied previously. To improve the prognosis and survival of patients with cTTP and iTTP, we propose to conduct a prospective study to observe the efficacy and safety of aspirin in patients with cTTP and iTTP in remission.",[25],"NOT_YET_RECRUITING","2022-09-30",{"date":106,"type":46},"2022-10-05",{"date":108,"type":19},"2022-10-01",{"date":110,"type":19},"2028-09-30",{"name":112,"class":53},"The First Affiliated Hospital of Soochow University"]